Exercise prior to assisted fertilization in overweight and obese women (FertilEX): study protocol for a randomized controlled trial by unknown
STUDY PROTOCOL Open Access
Exercise prior to assisted fertilization in
overweight and obese women (FertilEX):
study protocol for a randomized
controlled trial
Kari Margrethe Lundgren1, Liv Bente Romundstad2,3, Vidar von Düring2, Siv Mørkved3,4, Sigrun Kjøtrød2,5
and Trine Moholdt1,2*
Abstract
Background: Overweight and obese women show reduced conception rates compared to women of normal
weight. Insulin resistance and increased amount of visceral fat may be important mechanisms for reduced fertility
in these women. Exercise training, in particular with high intensity, has previously been found to improve insulin
sensitivity in overweight subjects. This study will assess if regular high-intensity interval training will improve the
pregnancy rate after assisted fertilization compared to usual care only in overweight and obese women. We hypothesize
that the intervention will improve pregnancy rate and insulin sensitivity compared to the control group.
Methods/design: The FertilEX study is a randomized, controlled trial in which 140 women with body mass index
(BMI) >25 kg/m2 accepted for assisted fertilization will be randomized (1:1) to an intervention group or a control
group. The intervention group will do high-intensity interval training three times per week for 10 weeks before
assisted fertilization. The control group will receive standard care assisted fertilization only. The primary outcome measure
is ongoing pregnancy 7–8 weeks after embryo transfer. Secondary outcome measures are insulin sensitivity, peak oxygen
uptake, brachial flow-mediated endothelial function, levels of reproductive hormones, and body composition.
Discussion: The results of this trial will provide knowledge about the effects of high-intensity exercise before assisted
fertilization in subfertile overweight/obese women. If the intervention leads to beneficial effects on outcome measures,
such programs should be considered as part of regular fertility care procedures for this population of women.
Trial registration: ClinicalTrials.gov: NCT01933633. Registered on 28 August 2013.
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Background
Obesity prevalence is increasing among women of repro-
ductive age. This has evident consequences for public
health, as obesity is associated with several chronic diseases
and premature mortality [1, 2]. In addition, obesity is asso-
ciated with an increased risk of subfertility [3]. Women
who have a body mass index (BMI, in kg/m2) above 24
have a significantly elevated relative risk of subfertility
compared to women with lower BMIs [4]. Although the
exact mechanism through which fertility is affected by
body mass and body fat is uncertain, adipose tissue has
been shown to disturb the secretion and bioavailability of
sex hormones and to affect egg quality, via effects of insu-
lin, leptin, and adipokines [5, 6]. In addition to obesity
alone, polycystic ovary syndrome (PCOS) is a common
endocrine disorder affecting 6–20 % of women of repro-
ductive age [7] and is currently recognized as the leading
cause of anovulatory infertility.
The mechanisms underlying the intrinsic insulin re-
sistance in PCOS remain unclear, but potentially they
are associated with increased abdominal visceral fat [8].
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In other insulin resistant populations, exercise training has
consistently been shown to improve cardiovascular risk
factors and reduce the risk of type 2 diabetes [9–11]. Fur-
thermore, insulin sensitivity has been found to increase
after a period of exercise training [10, 12]. Sim et al. [13]
found significantly improved pregnancy rates after a 12-
week weight loss program including exercise advice and
diet intervention in obese women undergoing assisted
fertilization. A recent observational study [14] also indi-
cated that regular physical activity is associated with im-
proved fertility in obese women going through fresh in
vitro fertilization (IVF) or intracytoplasmic sperm injec-
tion (ICSI) cycles. Still, there is a considerable gap in the
research literature regarding the effects of exercise training
on fertility outcomes, and future research should focus on
well-designed, adequately powered studies to address this
gap [15]. In particular, research is needed on the isolated
effects of exercise training, i.e., in the absence of dietary
interventions. Also, there is a great need to understand
the potential mechanisms through which exercise training
can affect fertility.
In this article, we describe the design and methods of
the FertilEX trial, a randomized controlled trial of exer-
cise training prior to assisted fertilization in overweight
and obese women.
The primary aim of the FertilEX trial is to test the hy-
pothesis that overweight and obese women who exercise
regularly prior to assisted fertilization will improve their
pregnancy rate compared to women who only receive
usual care assisted fertilization. The FertilEX trial will in-
vestigate possible mechanisms for increased fertility after
exercising, such as insulin sensitivity, body composition
and fat distribution, secretion and bioavailability of sex
hormones, egg quality, cytokine levels, and blood markers
of low-grade inflammation. Furthermore, we will assess
the effects of exercise training on peak oxygen uptake, per-
ipheral arterial endothelial function, and blood pressure.
Methods
Objectives
Our main hypothesis is that high-intensity interval training
(HIT) before going into regular assisted fertilization with
IVF or ICSI will improve the pregnancy rate in overweight
and obese women. As a mechanistic explanation of the in-
creased pregnancy rate, we expect that insulin sensitivity
will improve in the women in the exercise group, and that
the amount of reproductive and metabolic hormones will
change towards normal values in these women.
Participants and setting
The trial is conducted at St. Olavs Hospital, Trondheim
University Hospital in collaboration with the Norwegian
University of Science and Technology (NTNU), Trondheim,
Norway. The trial includes women with a BMI >25 kg/m2
who are accepted for assisted fertilization at the St. Olavs
Hospital. The trial was designed following the Standard
Protocol Items: Recommendations for Interventional
Trials (SPIRIT) 2013 statement (see Additional file 1).
Inclusion and exclusion criteria are listed in Table 1.
To be included, the women must be willing to come to
Trondheim for baseline assessments and post-testing after
the intervention period. If allocated to the intervention
group, the women must be willing to attend supervised
training until they are familiarized with the training proto-
cols and to continue to do HIT for 10 weeks.
The recruitment started in November 2013 and will
continue until the needed number of participants is in-
cluded, anticipated until the end of 2018. Participating
women in the training group get a free membership at a
local gym during the intervention period, and women in
the control group get a gift from the gym worth $85 US
dollars.
Randomization and allocation
Participants are stratified for PCOS (yes/no) and ran-
domly assigned to either the intervention or control
group after initial assessments in a 1:1 manner, as out-
lined in the flow diagram (Fig. 1). Randomization is
performed by a web-based randomization system devel-
oped and administered by the Unit of Applied Clinical
Research, Institute of Cancer Research and Molecular
Medicine, NTNU, Trondheim, Norway. The randomization
is in blocks with varying block size.
Intervention
The exercise training program consists of HIT performed
three times per week for 10 weeks. In two of the weekly
sessions, the participants perform intervals with an intensity
of 85–95 % of individual heart rate maximum for 4 minutes,
repeated four times (Fig. 2a). In the third weekly exercise
session, they perform intervals with maximum intensity
that can be sustained for 1 minute, repeated 10 times
(10 × 1) (Fig. 2b). All exercise training is preferably
done as treadmill walking or running. In case of trouble
with walking on a treadmill, other forms of exercise
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Age ≥18 years Current high-intensity exercise
training ≥2 times per week
Accepted for assisted fertilization Current or previous Metformin® use
(with wash-out period of >4 weeks)
BMI >25 kg/m2 Physical impairments limiting
exercise training
Able to come for assessments
at baseline and follow-up
Unable to follow verbal and written
instructions in Norwegian or English
Unwilling to suspend fertility
treatment for 10 weeks
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(bicycle, etc.) are used. This exercise regime has previously
been found to improve insulin resistance by 17 % in
women with PCOS [16]. The participants attend super-
vised exercise sessions until they are familiar with the
training protocols. Thereafter, they continue exercising at
the hospital or at a local gym. The participants wear heart
rate monitors (Polar RCX3, POLAR, Oulu, Finland) at all
training sessions to ensure that the exercise intensity is as
prescribed. Heart rate data will be stored in a personal on-
line training diary (http://www.polar.com) for use in ana-
lyses of compliance and exercise intensity. Exercise
intensity is checked regularly throughout the intervention
period by the study personnel. After the 10-week initial
training period, all women follow standard care assisted
fertilization, as described in the next paragraph. They are
also encouraged to exercise as described above in the
weeks of the fertility treatment until ovulation induction.
Thus, the total exercise period is 13–15 weeks, depending
on the fertility treatment protocol chosen by the treating
physician. Women in the control group receive regular
advice from the hospital staff about physical activity
(usual care).
The fertility treatment includes an ovarian stimulation
protocol, which is individualized for each patient according
to standardized routines at the Fertility Unit, St. Olavs
Hospital. We assume that the different protocols will
be equally distributed in the interventional and control
groups. The treatment includes either a short or a long
stimulation protocol. The selection of protocol is done
by the treating physician, who is blinded for group alloca-
tion. The treatment usually starts with a spontaneous onset
of the period or by the use of progestins for women with
long intervals between their menstrual bleedings. Prior to
ovarian stimulation with gonadotropins, a urine hCG test
to exclude pregnancy is taken by the patients at home. For
the short ovarian stimulation protocol, one out of the three
gonadotropins (Puregon®, Gonal-F®, or Menopur®) is ad-
ministrated daily from cycle day 2 or 3. The antagonist
(Orgalutran® 0.25 s.c.) is administered from the 5th treat-
ment day. In the long gonadotropin releasing hormone
(GnRH) agonist protocol, pituitary suppression is initiated
with 800 μg nafarelin (Synarela® nasal spray) 5–7 days be-
fore the estimated start of the next menstrual bleeding and
continued until the end of gonadotropin administration.
Gonadotropin treatment starts after at least 14 days on
GnRH agonist downregulation. Ovulation is induced by
hCG injection (Ovitrelle 250 μg s.c.) when at least three
follicles measure >17 mm. Ovum pick up is performed
transvaginally 36 h later. The method used for fertilization
is either IVF or ICSI. The day of embryo replacement is
day 2, 3, or 5 after oocyte retrieval. Luteal phase support is
given for 2 weeks. The patients take a urine hCG test
14 days after embryo replacement. For patients with a posi-
tive pregnancy test, a vaginal ultrasound examination is
performed by 7 to 8 weeks of gestation.
Study assessment visits
Participants come for research visits at baseline and after
the intervention period (10 weeks) (Fig. 1). Clinical data
collected by the hospital recordings during the treatment
will be available for the study investigators.
Outcome measures
The primary outcome measure is ongoing pregnancy,
defined as the sonographic evidence of intrauterine ges-
tational sac and fetal heart activity at 7 to 8 weeks of
gestation. If not pregnant, the women will either do an-
other IVF/ICSI cycle or are evaluated as not suitable for
further treatment cycles, based on the treating physician’s
decision. They will be considered as a negative for the pri-
mary outcome if not pregnant after the initial cycle.
Fig. 1 Participant flow through the FertilEX study
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Secondary outcome measures are insulin sensitivity,
levels of reproduction-related hormones (luteinizing hor-
mone (LH), follicle-stimulating hormone (FSH), prolactin,
anti-Müllerian hormone (AMH), testosterone, free andro-
gen index (FAI), sex hormone-binding globulin (SHBG)),
peak oxygen uptake, brachial flow-mediated endothelial
function, body weight, body composition, quality of life,
physical activity, and diet. Also, the Fertility Unit system-
atically registers the number of eggs retrieved, the propor-
tion of fertilized eggs and embryo quality, and pregnancy
outcome data. These data will be available for the study
investigators.
We measure insulin sensitivity by the gold standard,
the hyperinsulinemic-euglycemic clamp, using a modifi-
cation of the method originally described by De Fronzo
et al. [17]. The subjects are placed in an adjustable bed
in the supine position in a quiet and temperature stable
room. Catheters are inserted in the right and left antecu-
bital veins. The left catheter is used for blood sampling
and the right for infusion of insulin and glucose. The left
arm is placed in a heat package to enhance flow. Initial
samples are collected to determine fasting glucose and
insulin concentrations. After 30 min rest, human insulin
(Actrapid®, Novo Nordisk, Bagsvaerd, Denmark), diluted in
500 mL NaCl 0.9 % to 300 mU/mL, is infused at a rate of
40 mU/m2/min, and maintained for the entire test. Plasma
glucose concentration is measured every 5th minute (EKF
Biosen C-line Sport, EKF diagnostic GmbH, Barleben,
Germany) and kept at about 5.0 mmol/L for at least
30 min by adjusted infusion of 20 % glucose. Blood
samples for assessing plasma insulin are taken at 30, 60,
90, and 120 min, as well as every 10th minute during the
last 30 min of the test. The steady-state glucose infusion
rate (GIR) is calculated for the last 30 min of the test, and
Fig. 2 Training protocols. a) 4 × 4 min interval training. b) 10 × 1 min interval training
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the average GIR during this period will be used as the
measure of insulin sensitivity. The homeostasis model as-
sessment of insulin resistance (HOMA-IR) [18] will also
be calculated.
Blood samples are obtained in the morning after a ≥10 h
overnight fast and will be analyzed for concentrations of
lipids, glucose, hemoglobin, glycated hemoglobin (HbA1c),
albumin, high-sensitive C-reactive protein (CRP), and insu-
lin C-peptide. The hormone assays include the evaluation
of the above-mentioned reproduction-related hormones, as
well as insulin, thyroid-stimulating hormone, leptin, and
adiponectin. All analyses are conducted according to stand-
ard procedures at the Department of Medical Biochemistry,
St. Olavs Hospital. Biological materials are stored at the
Regional Biobank of Central Norway. Blood and urine
samples are also collected and stored at the Regional
Biobank of Central Norway for later analyses not yet
planned. The Biobank is approved by the Data Inspect-
orate of Norway and by the Regional Committee for
Medical Research Ethics. All information in the Bio-
bank is handled according to the guidelines of the Data
Inspectorate. Samples are stored with a unique identity
number, corresponding to the participant’s identity
number in the study, and with data on what the sample
contains and when it was taken.
Peak oxygen uptake is measured in an incremental
test to exhaustion by a direct ergospirometry system
with a mixing chamber (Oxygen Pro, Erich Jaeger GmbH,
Hoechberg, Germany) on a treadmill (Woodway USA
Inc., Waukesha, WI, USA). A leveling off of oxygen uptake
despite increased workload and a respiratory exchange
ratio ≥1.05 are used as criteria for peak oxygen uptake.
Measurements of peak oxygen uptake are performed at
the core facility NeXt Move, Norwegian University of
Science and Technology (NTNU).
Brachial flow-mediated endothelial function is measured
by high-resolution vascular ultrasound (14 MHz Doppler
probe, Vivid 7, GE Vingmed Ultrasound AS, Horten,
Norway) according to current guidelines [19, 20]. The sub-
jects are asked to refrain from strenuous physical activity
for ≥48 h before the assessments, and measurements are
obtained after a ≥10 h overnight fast. Measurements
are conducted in a quiet and temperature stable room
(22–24 °C) after 20 min of rest in a supine position.
Baseline images are taken before occluding the fore-
arm’s distal part by inflation of a pneumatic cuff (SC10,
D.E. Hokanson, Inc., Bellevue, WA, USA) to 250 mmHg
for 5 min. A longitudinal image of arterial diameter and
pulse wave velocity signals is recorded continuously for
3 min after cuff release. An integrated electrocardiogram
(ECG) is used to assess the diameter according to the car-
diac cycle.
Body weight, fat mass, and fat-free mass are mea-
sured using bioelectrical impedance analysis (InBody
720, Biospace CO, Ltd., Seoul, Korea). Additionally,
waist circumference is measured at the level of the um-
bilicus to further estimate the distribution of body fat.
Psychological well-being and quality of life are measured
using standardized questionnaires, the Psychological
General Well-Being Inventory [21] and the generic SF-
36 quality of life questionnaire [22], respectively.
Physical activity is registered by questionnaires and by ac-
tivity monitors (SenseWear, BodyMedia, Inc., Pittsburgh,
PA, USA) at baseline and after 10 weeks. The subjects wear
the activity monitor for five days: three weekdays and two
weekend days. Diet is registered by an electronic stan-
dardized food frequency registration system [23] for
two weekdays and one weekend day.
Power calculation and statistical analyses
A clinical pregnancy rate of 0.30 during the first treat-
ment cycle can be expected in this patient group. As the
research hypothesis of this study is original, we have lit-
tle previous data to support the power calculation. Based
on a previous pilot study on giving advice about exercise
and diet to improve pregnancy rates [24], we expect that
the pregnancy rate in the intervention group will be in-
creased to 0.55. With a statistical power of 0.80 and a
significance level of 0.05, it is estimated that 61 patients
are needed in each group to demonstrate the increased
pregnancy rate. To allow for an expected 15 % dropout,
we will include 140 participants in the study. We will
analyze the data using the intention-to-treat principle
(main analysis). Since dropout is one of the main con-
cerns in studies of lifestyle modifications, we will also
analyze the data with a per protocol analysis, excluding
women in the intervention group who did not follow the
prescribed intervention (defined as attending less than
80 % of the exercise sessions). As women in the control
group might start exercising on their own, in the per
protocol analyses we will exclude women in that group
reporting to do high-intensity endurance training (making
them breathe heavily) twice weekly or more during the
intervention period. The proportion of women with on-
going pregnancy in the intervention and control groups
will be compared using stratified (for PCOS/not PCOS)
analysis of 2 × 2 tables. Missing data regarding pregnancy
and fertilization outcome will be imputed with a negative
result or zero; i.e., if no oocytes are collected during the
assisted fertilization, the fertilization rate will be regarded
as missing. The null hypothesis is that the proportion is
equal in both groups, while the alternative hypothesis is
that the proportion is larger in the intervention group.
Secondary outcomes will be analyzed using analysis of co-
variance (ANCOVA), as suggested by Vickers and Altman
[25]. We will use intervention group (exercise/control) as
a fixed factor in the analyses and the baseline value of each
outcome measure and PCOS status (PCOS/not PCOS) as
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covariates. When data on secondary outcomes are miss-
ing, we will use multiple imputation if we can assume that
the data are missing at random. If we assume that the data
are not missing at random, we will analyze only available
data.
Blinding
Baseline measurements, except for activity monitoring,
are done before randomization. Assessments after the
interventional period are done both blinded (insulin sen-
sitivity, blood analyses, reproduction-related hormones,
clinical data collected by the hospital during fertility
treatment) and non-blinded (peak oxygen uptake, flow-
mediated dilatation assessments). However, the analysis
of the flow-mediated dilatation will be done blinded.
Discussion
Lifestyle interventions, including regular exercise, healthful
diet, and weight loss, are recommended to improve fertility
in overweight and obese women [26]. At present, there are
no evidenced-based guidelines on exercise training pro-
grams to improve fertility. We also need more knowledge
about the underlying mechanisms for improvements in fer-
tility after a period of exercise training. We have presented
the rationale and design of a randomized controlled trial
for investigating the effect of regular HIT in subfertile
overweight/obese women. As insulin resistance and vis-
ceral fat deposition are thought to be central mechanisms
contributing to decreased fertility in overweight/obese
women [6, 27], we hypothesize that an intervention pro-
gram designed to improve insulin sensitivity and reduce
visceral fat will improve the success rate after assisted
fertilization. We argue that this study will contribute
important knowledge for further recommendations re-
garding lifestyle interventions in obesity-associated fe-
male subfertility.
To our knowledge, this is the first study of HIT as an
approach to increase pregnancy rate among overweight
and obese women referred to assisted fertilization. If
successful, this study will bring new knowledge on pre-
ferred procedures to increase fertility rates in this popula-
tion and offer guidance to clinicians treating these women.
Trial status and change in study protocol after trial
initiation
We are recruiting participants for the FertilEX study. As
of March 2016, we have included 16 women in the
study. We made a change to the study protocol on 16
February 2016, and from this time point on, the women
allocated to the control group no longer wait for 10 weeks
before the assisted fertilization treatment starts. This was
done because we experienced that several women would
not like to participate in the study as they felt that their
treatment would be delayed. This study change therefore
implies there will be no assessments after 10 weeks for the
women in the control group. Also, as of February 2016,
we started to include patients from a second fertility
center, named Spiren Fertility Clinic, in Trondheim,
Norway. This change was made to increase the recruit-
ment to the study.
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